Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
June 20, 2023 07:00 ET
|
Fulcrum Therapeutics, Inc.
RANDOLPH, Mass. and CAMBRIDGE, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics (Nasdaq: FULC) announce the launch of Project Mercury, a...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2023 16:54 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
May 15, 2023 07:05 ET
|
Fulcrum Therapeutics, Inc.
― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD)...
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
May 15, 2023 07:00 ET
|
Fulcrum Therapeutics, Inc.
— Industry veteran brings more than 20 years of experience; will assume role effective July 1st — — During transition period Mr. Sapir will serve as special advisor to the interim CEO and president...
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
May 08, 2023 16:05 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023 18:06 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023 17:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces CFO Resignation
April 05, 2023 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2023 17:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
March 09, 2023 07:00 ET
|
Fulcrum Therapeutics, Inc.
― Company is working to address clinical hold on the Investigational New Drug application for FTX-6058 for the potential treatment of sickle cell disease ― ― FTX-6058 data from 12 mg cohort of Phase...